MoonLake Immunotherapeutics (MLTX)
Develops sonelokimab for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis.
$15.02
Pre-market−0.05 (−0.33%)
At close$15.07(−0.40%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions187 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 85.64% | 72.88M shares | |
| Insiders3 holders · as of Jul 29, 2026 | 3.50% | 2.98M shares | |
| Otherremainder | ≈ 10.86% | 9.24M shares |
85.11M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Jun 30, 2026
187 holders · 72.88M shares · 45 new positions · 117 increased · 45 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BVF Inc/IL | 16.00M | 18.80% | 0 | Aug 14, 2026 |
| Deep Track Capital, LP | 7.00M | 8.22% | +590.2K | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 4.28M | 5.03% | +4.28M | Aug 14, 2026 |
| D. E. Shaw & Co., Inc. | 3.37M | 3.95% | +974.8K | Aug 14, 2026 |
| Cormorant Asset Management, LP | 3.21M | 3.77% | −1.28M | Aug 14, 2026 |
| Jupiter Topco LLC | 3.09M | 3.63% | +3.09Mnew | Aug 14, 2026 |
| Logos Global Management LP | 2.68M | 3.14% | +1.18M | Aug 14, 2026 |
| Weiss Asset Management LP | 2.58M | 3.03% | +873.5K | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Biotechnology Value Fund L P | 10.20% | 8.30M | 13D | Jun 29, 2026 ↗ |
| Deep Track Capital, LP | 6.46% | 4.61M | 13G | Nov 12, 2025 ↗ |
| Cormorant Asset Management, LP | 6.25% | 4.48M | 13G | May 15, 2026 ↗ |
| T. Rowe Price Investment Management, Inc. | 5.30% | 4.28M | 13G | Aug 14, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 27, 2026 | Kristian Reichofficer: Chief Scientific Officer | Sale | 1,100 | $20.00 | 2,711,198 |
| Jul 22, 2026 | Kristian Reichofficer: Chief Scientific Officer | Sale | 2,448 | $20.00 | 2,712,298 |
| Jul 21, 2026 | Kristian Reichofficer: Chief Scientific Officer | Sale | 50,000 | $20.02 | 2,714,746 |
| Jul 20, 2026 | Kristian Reichofficer: Chief Scientific Officer | Sale | 43,700 | $20.09 | 2,764,746 |
| Jul 15, 2026 | Kristian Reichofficer: Chief Scientific Officer | Sale | 16,105 | $20.01 | 2,808,446 |
| Jul 10, 2026 | da Silva Jorge Santosdirector, officer: Chief Executive Officer | Sale | 68,289 | $20.02 | 2,774,893 |
| Jul 9, 2026 | da Silva Jorge Santosdirector, officer: Chief Executive Officer | Sale | 33,936 | $20.01 | 2,843,182 |
| Jul 1, 2026 | da Silva Jorge Santosdirector, officer: Chief Executive Officer | Sale | 47,775 | $20.03 | 2,877,118 |
| Jun 22, 2026 | Matthias Bodenstedtofficer: Chief Financial Officer | Sale | 39,120 | $22.04 | 1,115,435 |
| Jun 18, 2026 | Matthias Bodenstedtofficer: Chief Financial Officer | Sale | 2,794 | $19.60 | 1,154,555 |
CongressHouse and Senate disclosures
Not reported.